Key facts
- The FDA will hold a meeting to reconsider the safety and effectiveness of several popular peptide injections.
- The panel includes doctors and pharmacists with financial ties to the peptide industry.
- Many pharmaceutical industry experts consider these peptides illegal, unapproved drugs.
- Peptides are promoted for muscle building, injury healing, and anti-aging, with limited evidence.
- Some panel members run clinics that sell peptide injections and other unapproved therapies.
- A panelist's mother, a Republican member of Congress, previously advocated for relaxing FDA restrictions on peptides.
The U.S. Food and Drug Administration (FDA) is set to reconsider the safety and effectiveness of several popular peptide injections next month, with a newly announced panel that includes individuals who have deep financial ties to the burgeoning industry of unproven chemicals. This marks a shift from previous panels, which were composed of academics and researchers.
The agency's new group primarily consists of health professionals who actively prescribe, produce, or promote peptides, substances that have gained popularity as a wellness trend among athletes, influencers, and celebrities. These peptides are often sold online and promoted by wellness clinics with claims of building muscle, healing injuries, and promoting youthfulness, despite a lack of substantial evidence. Sellers frequently circumvent regulations by labeling products as "for research use only."
Several panel members have direct financial interests in the peptide market. Dr. Haleem Mohammed operates clinics in Florida selling peptide injections alongside other unapproved therapies. Dr. Gabriel Alizaidy offers consultations on peptides and hormones and promotes them on social media platforms like Instagram and TikTok. Bobby Harshbarger, a Tennessee state senator, is also a pharmacist at his family's pharmacy, which sells compounded medications. His mother, U.S. Representative Diana Harshbarger, has previously called on the FDA to ease restrictions on several peptides.
Health Secretary Robert F. Kennedy Jr. has been a vocal supporter of peptides, stating he is a "big fan" and has used them for injury recovery. This approach aligns with his broader efforts to reshape U.S. health policy. Critics have pointed out that previous FDA panels, composed of university experts, had voted against numerous peptide ingredients due to safety concerns. The FDA's advisory meetings are subject to transparency rules, requiring disclosure of financial stakes, though experts with conflicts are permitted to serve if their expertise is deemed to outweigh the potential conflict.